Literature DB >> 18700216

Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.

Jeffrey W Swanson1, Marvin S Swartz, Richard A Van Dorn, Jan Volavka, John Monahan, T Scott Stroup, Joseph P McEvoy, H Ryan Wagner, Eric B Elbogen, Jeffrey A Lieberman.   

Abstract

BACKGROUND: Violence is an uncommon but significant problem associated with schizophrenia. AIMS: To compare antipsychotic medications in reducing violence among patients with schizophrenia over 6 months, identify prospective predictors of violence and examine the impact of medication adherence on reduced violence.
METHOD: Participants (n=1445) were randomly assigned to double-blinded treatment with one of five antipsychotic medications. Analyses are presented for the intention-to-treat sample and for patients completing 6 months on assigned medication.
RESULTS: Violence declined from 16% to 9% in the retained sample and from 19% to 14% in the intention-to-treat sample. No difference by medication group was found, except that perphenazine showed greater violence reduction than quetiapine in the retained sample. Medication adherence reduced violence, but not in patients with a history of childhood antisocial conduct. Prospective predictors of violence included childhood conduct problems, substance use, victimisation, economic deprivation and living situation. Negative psychotic symptoms predicted lower violence.
CONCLUSIONS: Newer antipsychotics did not reduce violence more than perphenazine. Effective antipsychotics are needed, but may not reduce violence unrelated to acute psychopathology.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18700216      PMCID: PMC2801826          DOI: 10.1192/bjp.bp.107.042630

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  31 in total

1.  Antiaggressive effect of quetiapine in a patient with schizoaffective disorder.

Authors:  L Citrome; M Krakowski; W M Greenberg; E Andrade; J Volavka
Journal:  J Clin Psychiatry       Date:  2001-11       Impact factor: 4.384

2.  Victimization: a link between mental illness and violence?

Authors:  V A Hiday; J W Swanson; M S Swartz; R Borum; H R Wagner
Journal:  Int J Law Psychiatry       Date:  2001 Nov-Dec

3.  Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Authors:  Jan Volavka; Pal Czobor; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Miranda Chakos; Jeffrey A Lieberman
Journal:  Am J Psychiatry       Date:  2002-02       Impact factor: 18.112

4.  Violence and delusions: data from the MacArthur Violence Risk Assessment Study.

Authors:  P S Appelbaum; P C Robbins; J Monahan
Journal:  Am J Psychiatry       Date:  2000-04       Impact factor: 18.112

Review 5.  Violence and schizophrenia: examining the evidence.

Authors:  Elizabeth Walsh; Alec Buchanan; Thomas Fahy
Journal:  Br J Psychiatry       Date:  2002-06       Impact factor: 9.319

6.  Criminal offending in schizophrenia over a 25-year period marked by deinstitutionalization and increasing prevalence of comorbid substance use disorders.

Authors:  Cameron Wallace; Paul E Mullen; Philip Burgess
Journal:  Am J Psychiatry       Date:  2004-04       Impact factor: 18.112

7.  Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.

Authors:  Jan Volavka; Pal Czobor; Karen Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Jeffrey A Lieberman
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

8.  Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment.

Authors:  Jeffrey W Swanson; Marvin S Swartz; Eric B Elbogen
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

9.  The social-environmental context of violent behavior in persons treated for severe mental illness.

Authors:  Jeffrey W Swanson; Marvin S Swartz; Susan M Essock; Fred C Osher; H Ryan Wagner; Lisa A Goodman; Stanley D Rosenberg; Keith G Meador
Journal:  Am J Public Health       Date:  2002-09       Impact factor: 9.308

10.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development.

Authors:  T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Matthew J Byerly; Ira D Glick; Jose M Canive; Mark F McGee; George M Simpson; Michael C Stevens; Jeffrey A Lieberman
Journal:  Schizophr Bull       Date:  2003       Impact factor: 9.306

View more
  50 in total

1.  An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital.

Authors:  Nina Baruch; Mrigendra Das; Amit Sharda; Amlan Basu; Tom Bajorek; Callum C Ross; Samrat Sengupta; Fintan Larkin; Susan Young
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  Early risk factors for criminal offending in schizophrenia: a 35-year longitudinal cohort study.

Authors:  Asa Eriksson; Anders Romelsjö; Marlene Stenbacka; Anders Tengström
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2010-07-04       Impact factor: 4.328

Review 3.  Neuroimaging correlates of aggression in schizophrenia: an update.

Authors:  Matthew J Hoptman; Daniel Antonius
Journal:  Curr Opin Psychiatry       Date:  2011-03       Impact factor: 4.741

4.  Neural Mechanisms Underlying Affective Theory of Mind in Violent Antisocial Personality Disorder and/or Schizophrenia.

Authors:  Boris Schiffer; Christina Pawliczek; Bernhard W Müller; Jens Wiltfang; Martin Brüne; Michael Forsting; Elke R Gizewski; Norbert Leygraf; Sheilagh Hodgins
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

5.  Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.

Authors:  Jan Volavka; Pál Czobor; Leslie Citrome; Richard A Van Dorn
Journal:  CNS Spectr       Date:  2013-11-28       Impact factor: 3.790

6.  Schizophrenia--time to commit to policy change.

Authors:  W Wolfgang Fleischhacker; Celso Arango; Paul Arteel; Thomas R E Barnes; William Carpenter; Ken Duckworth; Silvana Galderisi; Lisa Halpern; Martin Knapp; Stephen R Marder; Mary Moller; Norman Sartorius; Peter Woodruff
Journal:  Schizophr Bull       Date:  2014-04       Impact factor: 9.306

Review 7.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements.

Authors:  Robert W Buchanan; Julie Kreyenbuhl; Deanna L Kelly; Jason M Noel; Douglas L Boggs; Bernard A Fischer; Seth Himelhoch; Beverly Fang; Eunice Peterson; Patrick R Aquino; William Keller
Journal:  Schizophr Bull       Date:  2009-12-02       Impact factor: 9.306

8.  Hostility in schizophrenia: An integrated analysis of the combined Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and the European First Episode Schizophrenia Trial (EUFEST) studies.

Authors:  J Volavka; R A Van Dorn; L Citrome; R S Kahn; W W Fleischhacker; P Czobor
Journal:  Eur Psychiatry       Date:  2015-12-04       Impact factor: 5.361

Review 9.  Schizophrenia and violence: systematic review and meta-analysis.

Authors:  Seena Fazel; Gautam Gulati; Louise Linsell; John R Geddes; Martin Grann
Journal:  PLoS Med       Date:  2009-08-11       Impact factor: 11.069

10.  Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.

Authors:  Haya Ascher-Svanum; Allen W Nyhuis; Douglas E Faries; Daniel E Ball; Bruce J Kinon
Journal:  BMC Psychiatry       Date:  2010-01-28       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.